Sei Investments Co. increased its stake in Icon Plc (NASDAQ:ICLR) by 6.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 380,655 shares of the medical research company’s stock after acquiring an additional 24,572 shares during the period. Sei Investments Co. owned approximately 0.71% of Icon worth $65,553,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ICLR. Financial Counselors Inc. raised its holdings in Icon by 1.2% in the fourth quarter. Financial Counselors Inc. now owns 5,183 shares of the medical research company’s stock valued at $893,000 after buying an additional 60 shares during the period. Creative Planning raised its holdings in Icon by 2.8% in the fourth quarter. Creative Planning now owns 2,345 shares of the medical research company’s stock valued at $404,000 after buying an additional 64 shares during the period. UBS Asset Management Americas Inc. raised its holdings in Icon by 30.9% in the second quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock valued at $50,000 after buying an additional 77 shares during the period. FTB Advisors Inc. raised its holdings in Icon by 27.6% in the third quarter. FTB Advisors Inc. now owns 361 shares of the medical research company’s stock valued at $52,000 after buying an additional 78 shares during the period. Finally, Shine Investment Advisory Services Inc. raised its holdings in Icon by 10.7% in the fourth quarter. Shine Investment Advisory Services Inc. now owns 848 shares of the medical research company’s stock valued at $146,000 after buying an additional 82 shares during the period. 85.41% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts recently commented on the stock. UBS Group set a $160.00 price target on shares of Icon and gave the company a “hold” rating in a report on Friday, October 25th. Zacks Investment Research lowered shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Citigroup assumed coverage on shares of Icon in a report on Monday, January 6th. They issued a “neutral” rating and a $185.00 price target on the stock. Credit Suisse Group restated a “buy” rating and issued a $160.00 price target on shares of Icon in a report on Monday, October 28th. Finally, BidaskClub upgraded shares of Icon from a “hold” rating to a “buy” rating in a report on Friday, January 17th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Icon currently has a consensus rating of “Hold” and an average target price of $171.89.

Shares of ICLR remained flat at $$175.28 during mid-day trading on Friday. 125,632 shares of the stock were exchanged, compared to its average volume of 200,457. The stock has a market cap of $9.46 billion, a price-to-earnings ratio of 26.32, a price-to-earnings-growth ratio of 2.07 and a beta of 0.77. The firm has a 50-day moving average of $171.48 and a two-hundred day moving average of $158.25. Icon Plc has a 12 month low of $127.58 and a 12 month high of $176.98. The company has a current ratio of 2.03, a quick ratio of 2.03 and a debt-to-equity ratio of 0.28.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Further Reading: What is a resistance level?

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.